Evidence map›Paper›PMID 36945447›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Plasma NT1-tau and Aβ

Andrew M Stern, Kathryn L Van Pelt, Lei Liu, Amirah K Anderson, Beth Ostaszewski, Mark Mapstone, Sid O'Bryant, Melissa E Petersen, Bradley T Christian, Benjamin L Handen and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Andrew M SternORCID 0000-0002-8589-6891
Kathryn L Van Pelt
Lei Liu
Amirah K Anderson
Beth Ostaszewski
Mark Mapstone
Sid O'Bryant
Melissa E Petersen
Bradley T Christian
Benjamin L Handen
Dennis J Selkoe
Frederick Schmitt
Elizabeth Head
Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS) investigators
Brigham and Women's Hospital · USUniversity of California, Irvine · USUniversity of Kentucky · USUniversity of North Texas · USUniversity of Pittsburgh · USUniversity of Wisconsin–Madison · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, JOSEPH HYUNGWOO · 2020 to 2025
$103.7M
NIA NIH HHS U19 AG068054NIA NIH HHS U24 AG021886
6 · The paper itself

Abstract

Introduction: People with Down syndrome (DS) often develop Alzheimer disease (AD). Here we asked whether ultrasensitive plasma immunoassays for a tau N-terminal fragment (NT1-tau) and Aβ isoforms predict cognitive impairment. Methods: Plasma NT1-tau, Aβ Results: Linear mixed models for NT1-tau, Aβ Discussion: NT1-tau correlates with age and worse cognition in DS. Further validation of NT1-tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility.

Identifiers

PMID36945447
PMCPMC10029060
OpenAlexW4323824391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.